PRGO · PERRIGO Co plc

$10.47 -0.12 (-1.13%) At close · Jul 21

Market Cap

$1.48B

138.37M

Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.

Revenue

$4.25B -2.8%

FY2025

Net Income

-$1.43B -729.7%

FY2025

Gross Margin

35.14% -0.1pp

FY2025

Operating Margin

-26.39% -29pp

FY2025

Diluted EPS

-$10.29 -723.2%

FY2025

Operating Cash Flow

$238.5M -34.3%

FY2025

Chart any reported metric, KPI or segment over time — the full statement history lives here

Income Statement Balance Sheet Cash Flow All Metrics

Annual Quarterly

Line Item	3Y	5Y	10Y	TTM	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018	FY2017	FY2016	FY2015	FY2014
Revenue	-1.5%	+0.8%	-0.8%	$4.18B	$4.25B	$4.37B	$4.66B	$4.45B	$4.14B	$4.09B	$3.87B	$4.73B	$4.95B	$5.28B	$4.6B	$4.06B
Net Interest Income	—	—	—	-$173.1M	—	—	-$173.8M	-$156M	-$125M	-$127.7M	-$117.5M	-$128M	-$168.1M	-$216.6M	-$146M	—
Cost of Revenue	-2.7%	+1.2%	-0.5%	$2.75B	$2.76B	$2.83B	$2.98B	$3B	$2.72B	$2.59B	$2.44B	$2.9B	$2.97B	$3.23B	$2.89B	$2.61B
Gross Profit	+0.9%	0.0%	-1.4%	$1.43B	$1.49B	$1.54B	$1.68B	$1.46B	$1.42B	$1.49B	$1.43B	$1.83B	$1.98B	$2.05B	$1.71B	$1.45B
Gross Margin	—	—	—	—	35.14%	35.27%	36.09%	32.69%	34.22%	36.57%	37.05%	38.71%	40.02%	38.86%	37.2%	35.65%
Research & Development	-8.1%	-4.8%	-6.5%	$93.3M	$95.4M	$112.2M	$122.5M	$123.1M	$122M	$121.7M	$119.2M	$218.6M	$167.7M	$184M	$187.8M	$152.5M
Selling & Marketing	-3.4%	-0.7%	+5.1%	$510M	$526.5M	$546.6M	$641.8M	$584.8M	$536.4M	$545.5M	$538.7M	$595.7M	$598.4M	$665M	$319M	$208.6M
General & Administrative	-5.2%	-1.8%	+1.2%	$438.7M	$435.9M	$468M	$522.3M	$512.3M	$482M	$478.5M	$476.5M	$435.9M	$461.1M	$452.2M	$385.2M	$411.3M
Amortization of Intangibles	-4.1%	+1.0%	-7.1%	$222.4M	$222.7M	$228.5M	$265.8M	$252.4M	$210M	$212.2M	$219.6M	$333.6M	$349.6M	$356.8M	$464.5M	$281M
Depreciation & Amortization	-0.1%	-2.6%	-4.7%	$340.9M	$337.5M	$325.9M	$359.5M	$338.6M	$312.2M	$384.8M	$396.5M	$423.6M	$444.8M	$457M	$548.8M	$358.9M
Restructuring Charges	+19.2%	+86.3%	+30.3%	$117.6M	$71.9M	$110.1M	$42.2M	$42.5M	$16.9M	$3.2M	$25.9M	$21M	$61M	$31M	$5.1M	$47M
Total Operating Expenses	+23.9%	+16.3%	+10.5%	$2.97B	$2.62B	$1.43B	$1.53B	$1.38B	$1.01B	$1.23B	$1.26B	$1.6B	$1.38B	$4.05B	$964.8M	—
Operating Income	—	—	—	-$1.54B	-$1.12B	$112.9M	$151.9M	$78.9M	$410.4M	$265.2M	$174.7M	$236.5M	$598.2M	-$2B	$747.7M	$567M
Operating Margin	—	—	—	—	-26.39%	2.58%	3.26%	1.77%	9.92%	6.49%	4.51%	5%	12.09%	-37.87%	16.24%	13.96%
EBITDA	—	—	—	-$1.2B	-$784.7M	$438.8M	$511.4M	$417.5M	$722.6M	$650M	$571.2M	$660.1M	$1.04B	-$1.54B	$1.3B	$925.9M
Other Non-Operating Income	—	—	—	-$7.6M	-$13.2M	$900K	$10.4M	-$53.1M	-$26.7M	-$16.3M	$68.9M	-$6.1M	$10.1M	-$22.7M	—	-$12.4M
Equity in Earnings of Unconsolidated Entities	—	—	—	-$34.1M	—	-$1.5M	-$1.9M	-$1.5M	-$1.1M	—	—	—	$300K	-$4.1M	-$9.9M	$0
Pretax Income	—	—	—	-$1.71B	-$1.3B	-$80.7M	-$8.3M	-$139.1M	$258.7M	—	—	$290.6M	$280.1M	-$4.85B	$248M	$272.6M
Income Tax	—	—	-1.4%	$77.5M	$104.4M	$80M	-$3.9M	-$8.2M	$389.6M	-$38.3M	-$10.7M	$159.6M	$160.5M	-$835.5M	$120M	$67.3M
Net Income	—	—	—	-$1.82B	-$1.43B	-$171.8M	-$12.7M	-$140.6M	-$68.9M	-$162.6M	$146.1M	$131M	$119.6M	-$4.01B	$128M	$205.3M
Net Margin	—	—	—	—	-33.51%	-3.93%	-0.27%	-3.16%	-1.66%	-3.98%	3.78%	2.77%	2.42%	-75.99%	2.78%	5.06%
Comprehensive Income	—	—	—	-$1.75B	-$1.26B	-$344.9M	$25M	-$203.1M	-$428.4M	$93M	$200.9M	-$36.5M	$454.5M	-$4.08B	$90.8M	$267.9M
EPS (Basic) USD/shares	—	—	—	—	-$10.29	-$1.25	-$0.09	-$1.04	-$0.52	-$1.20	$1.07	$0.95	$0.84	-$28.01	$0.92	$1.78
EPS (Diluted) USD/shares	—	—	—	—	-$10.29	-$1.25	-$0.09	-$1.04	-$0.52	-$1.19	$1.07	$0.95	$0.84	-$28.01	$0.92	$1.77
Shares Outstanding (Basic Avg) shares	+1.0%	+0.4%	-0.1%	—	138.5M	137.4M	135.3M	134.5M	133.6M	136.1M	136M	137.8M	142.3M	143.3M	139.3M	115.1M
Shares Outstanding (Diluted Avg) shares	+1.0%	+0.2%	-0.1%	—	138.5M	137.4M	135.3M	134.5M	133.6M	137.2M	136.5M	138.3M	142.6M	143.3M	139.8M	115.6M

Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing. TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.

Capital Returned to Shareholders

Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2025: $798.9M in buybacks, $1.36B in dividends.

Price & Valuation

Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.

Valuation

EV/Revenue

—

Drug Manufacturers - Specialty & Generic median 2.27×

EV/EBIT

—

Drug Manufacturers - Specialty & Generic median 34.79×

P/E (TTM)

—

Drug Manufacturers - Specialty & Generic median 20.49×

Valuation over time computed as of each quarter's filing date

Revenue Breakdown

Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.

Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Consumer Self Care Americas	$2,585,300,000	$2,693,700,000	$2,962,300,000	$2,925,900,000	$2,693,100,000	$2,693,000,000	$2,487,700,000	$2,411,600,000
Consumer Self Care International	$1,667,700,000	$1,679,600,000	$1,693,300,000	$1,525,700,000	$1,445,600,000	$1,395,200,000	$1,382,200,000	$1,399,300,000
Other	—	—	—	—	—	—	$0	$0
RX Pharmaceuticals	—	—	$0	$0	$0	$0	$0	$920,800,000
All Other Segments	—	—	—	—	—	—	$0	$0
Material Reconciling Items	—	—	—	—	—	—	$0	$0

By Geography (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
United States	$2,540,100,000	$2,649,300,000	$2,916,800,000	$2,870,000,000	$2,565,900,000	$2,579,000,000	$2,360,300,000	$3,098,300,000
Europe	$1,616,300,000	$1,604,600,000	$1,622,500,000	$1,474,300,000	$1,393,000,000	$1,350,600,000	$1,335,800,000	$1,347,600,000
Other Geographical Areas	$96,700,000	$119,500,000	$116,300,000	$107,300,000	$179,800,000	$158,600,000	$173,800,000	$285,800,000
Ireland	$42,100,000	$39,600,000	$40,800,000	$29,300,000	$23,700,000	$29,800,000	$23,400,000	$25,700,000

By Product & Service (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Contract Manufacturing	$270,900,000	$306,200,000	$337,300,000	$350,100,000	$299,700,000	$261,400,000	$285,300,000	$300,500,000

Segment Operating Income

Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.

By Segment (USD)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Consumer Self Care International	-$228,800,000	$105,000,000	-$35,200,000	-$30,000,000	$36,100,000	$32,300,000	$19,600,000	$6,800,000
Consumer Self Care Americas	-$669,000,000	$269,900,000	$389,600,000	$366,100,000	$206,500,000	$465,000,000	$406,700,000	$174,400,000
RX Pharmaceuticals	—	—	$0	$0	$0	$0	$0	$214,600,000
All Other Segments	—	—	—	—	—	—	$0	$0
Material Reconciling Items	—	—	—	—	—	—	-$231,400,000	-$159,300,000

Operating Margin by Segment (%)

Component	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020	FY2019	FY2018
Consumer Self Care Americas	-25.9%	10%	13.2%	12.5%	7.7%	17.3%	16.3%	7.2%
Consumer Self Care International	-13.7%	6.3%	-2.1%	-2%	2.5%	2.3%	1.4%	0.5%
RX Pharmaceuticals	—	—	—	—	—	—	—	23.3%

Key facts CIK 1585364 CUSIP G97822103 13F (30d) 39 filings 39 filers Visit website Investor relations